tiprankstipranks
Trending News
More News >
Xintela AB (SE:XINT)
:XINT

Xintela AB (XINT) AI Stock Analysis

Compare
0 Followers

Top Page

SE

Xintela AB

(Frankfurt:XINT)

Rating:43Neutral
Price Target:
Xintela AB's stock is facing significant financial challenges, with persistent losses and negative equity being major concerns. The recent revenue growth is a positive sign but is overshadowed by the company's dependence on external financing and unprofitability. Technical indicators show a mixed outlook, while valuation metrics reflect the company's financial instability. Overall, Xintela AB requires substantial improvement to become a more attractive investment.

Xintela AB (XINT) vs. iShares MSCI Sweden ETF (EWD)

Xintela AB Business Overview & Revenue Model

Company DescriptionXintela AB (XINT) is a biotechnology company based in Sweden that focuses on the development and commercialization of cell therapy products and targeted cancer treatments. The company leverages its proprietary marker technology, XINMARK, to identify and select specific cell types for therapeutic use, primarily in the fields of regenerative medicine and oncology. Xintela's core products and services revolve around stem cell-based therapies for osteoarthritis and other musculoskeletal disorders, as well as targeted antibodies for the treatment of aggressive cancers.
How the Company Makes MoneyXintela AB primarily generates revenue through the development and commercialization of its proprietary cell therapy products and targeted cancer treatments. The company earns money by partnering with pharmaceutical companies and research institutions to co-develop therapies, licensing its technology, and potentially through future product sales once regulatory approvals are secured. Significant factors contributing to its earnings include collaborative agreements, research grants, and strategic partnerships that support the advancement of its clinical programs. Additionally, Xintela may benefit from milestone payments and royalties from commercialized products developed using its technology.

Xintela AB Financial Statement Overview

Summary
Xintela AB shows potential with increased revenue, but persistent operating losses and negative equity highlight financial instability. The company's cash flow is highly dependent on financing activities, and the negative financial ratios suggest a need for structural financial improvements to achieve long-term sustainability.
Income Statement
35
Negative
Xintela AB has shown significant revenue growth from 2023 to 2024, increasing from SEK 78,000 to SEK 4,215,000. However, the company continues to face substantial losses with a negative net profit margin and EBIT margin due to high operating expenses. The gross profit margin is strong at 100% due to the low cost of revenue, but earnings remain negative, indicating profitability challenges.
Balance Sheet
20
Very Negative
The company has a negative stockholders' equity, indicating financial distress. The debt-to-equity ratio is technically zero due to no debt, but this is overshadowed by the negative equity. The equity ratio is also negative, reflecting more liabilities than assets, posing a risk to financial stability.
Cash Flow
45
Neutral
Free cash flow improved slightly due to increased financing, but operating cash flow remains negative, indicating operational cash generation challenges. The company's reliance on external financing is significant, which could affect financial independence in the long-term.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
4.21M78.00K0.000.000.00
Gross Profit
3.66M78.00K-3.79M-3.50M-3.57M
EBIT
-39.45M-57.24M-69.06M-43.56M-33.90M
EBITDA
-38.90M-53.47M-64.83M-57.11M-30.33M
Net Income Common Stockholders
-39.19M-54.08M-66.22M-58.93M-52.92M
Balance SheetCash, Cash Equivalents and Short-Term Investments
16.68M7.81M8.34M9.94M33.60M
Total Assets
24.80M18.39M24.52M24.74M48.51M
Total Debt
0.000.000.000.0010.90M
Net Debt
-16.68M-7.81M-8.34M-9.94M-22.70M
Total Liabilities
30.75M14.02M18.74M20.80M20.91M
Stockholders Equity
-5.95M4.38M5.78M3.95M27.61M
Cash FlowFree Cash Flow
-40.70M-53.22M-39.60M-44.15M-21.71M
Operating Cash Flow
-40.70M-53.12M-39.49M-42.89M-21.33M
Investing Cash Flow
0.00-104.00K-27.52M-1.20M-329.00K
Financing Cash Flow
50.09M51.79M64.56M20.43M54.85M

Xintela AB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.44
Price Trends
50DMA
0.41
Positive
100DMA
0.41
Positive
200DMA
0.41
Positive
Market Momentum
MACD
0.01
Negative
RSI
52.29
Neutral
STOCH
74.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XINT, the sentiment is Positive. The current price of 0.44 is below the 20-day moving average (MA) of 0.44, above the 50-day MA of 0.41, and above the 200-day MA of 0.41, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 52.29 is Neutral, neither overbought nor oversold. The STOCH value of 74.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:XINT.

Xintela AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
62
Neutral
$11.93B10.60-7.51%3.00%7.40%-8.09%
54
Neutral
€413.69M-47.73%45.52%93.35%
47
Neutral
€77.18M-69.81%-17.91%22.80%
44
Neutral
€256.83M-18.79%21.85%
SEACE
43
Neutral
kr552.28M-138.29%39.92%
43
Neutral
€328.90M
5303.85%55.59%
36
Underperform
kr176.86M-54.29%-100.00%-17.35%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:XINT
Xintela AB
0.44
0.19
77.60%
SE:ACE
Ascelia Pharma AB
4.63
-1.89
-29.02%
SE:IMMU
Immunicum AB
5.20
-4.26
-45.03%
SE:ISOFOL
Isofol Medical AB
1.13
0.44
63.62%
SE:NXTCL
NextCell Pharma AB
1.11
-0.46
-29.04%
SE:XBRANE
Xbrane Biopharma AB
0.26
-0.04
-13.77%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.